Want to join the conversation?
$CELG announced 72-week results from the RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis. The RADIANCE trail met primary efficacy endpoint, reduction in cumulative number of total gadolinium-enhancing (GdE) lesions from week 12 to 24.
Planned to give Apple AirPods as a Christmas present to my beloved one. Looks like I need backup plans as $AAPL is delaying the release..!!
When you fall hard, I think you stay there for a long time.. I am looking at you $FTNT! After it released the earnings, the share price slipped and is staying around $30 for a long time.
$FOXA just entered into a preliminary deal with Sky plc under which it will acquire all shares, or should I say remaining shares for a total value of $23 billion. The sleeping fox catches no poultry, but this fox just caught something that’s a lot bigger than poultry.